New therapeutic options in gastrointestinal stromal tumors

Keyphrases

• Imatinib 100%
• New Therapeutics 100%
• Gastrointestinal Stromal Tumor 100%
• Therapeutic Potential 100%
• Drug Therapy 100%
• Tumor 50%
• Standard of Care 50%
• Malignancy 50%
• Poor Prognosis 50%
• Novel Therapies 50%
• Disease Status 50%
• Gleevec 50%
• Tyrosine Kinase Inhibitor 50%
• Metastatic Disease 50%
• Early Disease 50%
• Sunitinib 50%
• Tyrosine Kinase Receptor 50%
• Neoadjuvant 50%
• Molecular Markers 50%
• Intolerant 50%
• Treatment Paradigms 50%
• Disease-free Interval 50%
• Platelet-derived Growth Factor Receptor (PDGFR) 50%
• Resectable Disease 50%
• Activating mutation 50%
• Effective Compounds 50%
• Resistant Disease 50%
• Multi-targeted Tyrosine Kinase Inhibitors 50%
• Imatinib Resistance 50%
• Tyrosine Kinase Inhibitor Therapy 50%
• Adjuvant Imatinib 50%
• Complete Surgical Excision 50%
• Sutent 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Imatinib 100%
• Gastrointestinal Stromal Tumor 100%
• Protein Tyrosine Kinase Inhibitor 60%
• Diseases 60%
• Pharmacotherapy 40%
• Sunitinib 40%
• Neoplasm 20%
• Side Effect 20%
• Metastasis 20%
• Tyrosine Kinase Receptor 20%
• Molecular Marker 20%